Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.67 |
| ▸ | TSHR | P16473 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HTR7 | P34969 | 4/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6908658 | 0.91 | KDM4E (0.71) | KDM4ETSHRLMNAMAPTTDP1 | |
| SCHEMBL4753124 | 0.83 | KDM4E (0.81) | KDM4ETSHRLMNAMAPK1KMT2A | |
| SCHEMBL6903347 | 0.81 | KDM4E (0.73) | KDM4ETSHRLMNAMAPK1MEN1 | |
| SCHEMBL6902190 | 0.79 | LMNA (0.64) | KDM4ETSHRLMNAMAPK1MEN1 | |
| SCHEMBL6906347 | 0.79 | ALDH1A1 (0.78) | KDM4ETSHRLMNAMAPK1KMT2A | |
| SCHEMBL2316528 | 0.76 | KDM4E (0.77) | KDM4ETSHRLMNAMAPK1MEN1 | |
| SCHEMBL9831262 | 0.74 | KDM4E (0.64) | KDM4ETSHRLMNAMAPK1MEN1 | |
| SCHEMBL28191688 | 0.73 | KDM4E (0.63) | KDM4ETSHRLMNAMAPK1MEN1 | |
| SCHEMBL13727749 | 0.72 | KDM4E (0.68) | KDM4ETSHRLMNAMAPK1MEN1 | |
| SCHEMBL27921070 | 0.72 | KDM4E (0.62) | KDM4ETSHRLMNAMAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020052373-A1 | Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease | ZORN STEVIN H (US) | 2002-05-02 | — | — | US | claimed |
| EP-1201268-A2 | Combinations of D4 dopamine receptor antagonists with acetylcholine esterase inhibitors | Pfizer Products Inc. (US) | 2002-05-02 | — | — | EP | claimed |
| US-6121267-A | ADMINISTERING DOPAMINE ANTAGONIST TO TREAT PSYCHOLOGICAL DISORDER, I.E., SCHIZOPHRENIA | WARNER-LAMBERT COMPANY (US) | 2000-09-19 | — | — | US | claimed |
| WO-1997041108-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER-LAMBERT COMPANY (US) | 1997-11-06 | — | — | WO | claimed |
| US-20040048869-A1 | Combination treatment for depression, anxiety and psychosis | PFIZER INC | 2004-03-11 | — | — | US | disclosed |
| US-20020094986-A1 | Combination treatment for depression, anxiety and psychosis | PFIZER INC | 2002-07-18 | — | — | US | disclosed |
| EP-1213031-A2 | Combination treatment for depression, anxiety and psychosis comprising an antidepressant and/or anxiolytic and a D4 receptor antagonist | Pfizer Products Inc. (US) | 2002-06-12 | — | — | EP | disclosed |
| US-20020052373-A1 | Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease | ZORN STEVIN H (US) | 2002-05-02 | — | — | US | disclosed |
| EP-1201268-A2 | Combinations of D4 dopamine receptor antagonists with acetylcholine esterase inhibitors | Pfizer Products Inc. (US) | 2002-05-02 | — | — | EP | disclosed |
| US-6121267-A | ADMINISTERING DOPAMINE ANTAGONIST TO TREAT PSYCHOLOGICAL DISORDER, I.E., SCHIZOPHRENIA | WARNER-LAMBERT COMPANY (US) | 2000-09-19 | — | — | US | disclosed |
| US-5965560-A | AS DOPAMINE ANTAGONISTS AND ANTIPSYCHOTIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1999-10-12 | — | — | US | disclosed |
| WO-1997041108-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER-LAMBERT COMPANY (US) | 1997-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094986-A1 | Combination treatment for depression, anxiety and psychosis | HTR4, CHRNA4, GRM4 | KDM4E 3111/4885TSHR 94/4885LMNA 1496/4885 |
| US-20020052373-A1 | Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease | ACHE, BCHE, CHRM4 | KDM4E 1815/4885TSHR 905/4885LMNA 4258/4885 |
| US-20040048869-A1 | Combination treatment for depression, anxiety and psychosis | HTR4, CHRNA4, GRM4 | KDM4E 3111/4885TSHR 94/4885LMNA 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.